Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17574493 | 0.83 | CTSB (0.47) | CTSBCTSS | |
| SCHEMBL6844970 | 0.80 | CTSB (0.46) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL11929778 | 0.80 | CTSB (0.46) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL1927692 | 0.80 | CTSB (0.46) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL6844968 | 0.72 | CTSB (0.45) | CTSBCTSS | |
| SCHEMBL1926348 | 0.72 | CTSB (0.45) | CTSBCTSS | |
| SCHEMBL11929776 | 0.72 | CTSB (0.44) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13502724 | 0.71 | CTSB (0.39) | CTSBCTSS | |
| SCHEMBL8286269 | 0.70 | CTSB (0.42) | CTSBCTSS | |
| SCHEMBL12023453 | 0.70 | CTSB (0.42) | CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2461811-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |